FICTION · An Unfair Advantage Intervention
Fiction. Real history. Sourced below.
In October 2024, while still a public company, Walgreens described its own pharmacy model as unsustainable and announced it would close 1,200 stores. Nine years earlier it had agreed to pay a 48 percent premium to acquire several thousand more of them. Everything that happened in between, including a two-year antitrust fight the analysts called correctly, sits inside that gap.
I want to dissent from how this case is normally filed. It is taught as a lesson in regulatory risk, and the regulatory analysis was genuinely good, which is exactly what makes it useful to me as a diagnostic failure. A sound answer, produced rigorously, to a question that did not determine the outcome, is a more instructive error than sloppiness, because sloppiness is easy to guard against and this is not.
Full fiction disclosure and sourcing note
Eugene Spark is a fictional character from The Unfair Advantage by Todd Hagopian, analyzing the documented history of the Walgreens and Rite Aid transaction from the present day. He has never met, advised, or corresponded with anyone named here, and no dialogue, thought, or motive is invented for any real person. Facts come from the public record and are accurate as of 2026; the analysis is invented. Rite Aid’s bankruptcies involved opioid-related litigation among other liabilities; that is noted here as a matter of record and is not analysed.
- The Regulatory Analysis Was Correct and Nearly Irrelevant
- The Right-to-Win Matrix Was Run in Only One Direction
- The Deal Eroded in Public Over Three Years
- The Company Said It Out Loud in 2024
- The Enforcement Question Is Genuinely Open
- By the Numbers
- The Monday Morning Playbook
- About the Stagnation Assassin
The Regulatory Analysis Was Correct and Nearly Irrelevant
In October 2015 Walgreens agreed to acquire Rite Aid at $9.00 a share, a 48 percent premium, for an enterprise value around $17.2 billion. The competitive objection was visible on day one and did not require specialist insight: the Federal Trade Commission assesses pharmacy competition market by market rather than nationally, and across hundreds of local markets Rite Aid was the principal alternative to Walgreens.
The structural trap follows immediately. The stores carrying the most synergy value are the ones in the most concentrated markets, which are precisely the stores a regulator will demand you divest. Synergy and remedy run in opposite directions, so the more valuable the deal, the less of it survives review.
That analysis was right, and the companies publicly maintained the opposite. It is also, in retrospect, close to irrelevant, and my objection to the standard telling is that treating it as the lesson teaches people to sharpen the wrong instrument.
The Right-to-Win Matrix Was Run in Only One Direction
The Right-to-Win Matrix asks not where a company can compete but where it can genuinely win, and its operating rule is recursion: keep segmenting until the segments actually differ, because the answer changes as the cuts get finer.
Every party here ran that recursion downward with real rigour. Walgreens segmented to the local market. The FTC segmented to the local market. Both concluded, correctly, that certain markets could not support the combination. Thousands of hours went into cutting the problem finer.
Nobody ran it upward. The prior question is whether the category itself is a cell that can be won, and by 2015 the evidence was available: reimbursement margins on the pharmacy side were being compressed by pharmacy benefit managers, front-of-store convenience revenue was migrating to Amazon and the big-box chains, and the industry carried debt from years of over-opening. Winning share of that pool is a different proposition from winning share of a growing one.
There is a doctrinal version of the same point. The transaction was underwritten as a LEAD move, a decade-scale position built through consolidation, when the condition on the ground was closer to WAR, a business stagnating and needing its orthodoxies broken rather than its footprint enlarged. Applying the right discipline to the wrong condition produces exactly this: excellent work, correctly executed, pointed at a question whose answer changed nothing.
The Deal Eroded in Public Over Three Years
The sequence is worth stating plainly because it shows the erosion happening in daylight. The $9.00 price was cut to $7.00 in early 2017 and then floored at $6.50. The companies proposed divesting roughly 865 stores to Fred’s, a much smaller regional chain, as a remedy; the FTC concluded Fred’s could not credibly replace Rite Aid as a competitor and the remedy failed.
In June 2017 the merger was abandoned. Walgreens paid a $325 million termination fee and pivoted to buying assets instead: first a proposed 2,186 stores for $5.175 billion, then, after further review, a cleared purchase of 1,932 stores for $4.375 billion, completed in 2018. A $17.2 billion combination had become a fragment worth about a quarter of it, and the purchasing and operational synergies that justified the original premium depended on a combination that never occurred.
Rite Aid, left independent and weaker, attempted a merger with Albertsons as an alternative. Shareholders rejected it. By late 2018 the company had failed at two transactions in three years and had no strategic path left.
The Company Said It Out Loud in 2024
Six years later, Walgreens stated the conclusion itself. In October 2024, still publicly traded, it described the prevailing pharmacy model as unsustainable and announced the closure of 1,200 underperforming locations over three years. That is the acquirer, having spent nine years and billions of dollars fighting to own more stores, declaring the format uneconomic.
What followed for both parties is a matter of record. Rite Aid filed for Chapter 11 in 2023 under debt and litigation including opioid-related claims, emerged in 2024, filed again in May 2025, and completed a full liquidation late that year, transferring prescription files to competitors after 63 years in business.
Walgreens was removed from the Dow Jones Industrial Average in 2024 and replaced by Amazon. In August 2025, Sycamore Partners completed a take-private at $11.45 a share, roughly $10 billion of equity and around $23.7 billion including debt and contingent payments, ending the company’s long run as a public business. Under private ownership the pace increased: 628 corporate roles were eliminated in February 2026 across the Deerfield headquarters and a Houston distribution centre, with around 100 further store closures planned this year and the format itself being reconsidered in favour of smaller pharmacy-focused sites.
The Enforcement Question Is Genuinely Open
One consequence deserves stating carefully, because it is uncomfortable and I do not think it has an obvious answer.
The FTC blocked the full combination specifically to preserve competition between Walgreens and Rite Aid in local markets where they were the main alternatives. Rite Aid subsequently liquidated on its own and its prescription files went to CVS and Walgreens. The concentration that enforcement prevented in 2017 arrived anyway in 2025, by insolvency rather than by transaction.
That does not make the enforcement wrong. The agency applied the law to the facts in front of it, and it is not the FTC’s role to forecast which competitor will fail. But merger review does rest on an implicit assumption, which is that the firm being protected would otherwise have survived to compete. In a category whose economics are deteriorating, that assumption can simply be false, and here it was.
The related observation is that the pressure everyone now identifies as the cause, reimbursement compression by pharmacy benefit managers, drew serious regulatory and congressional attention only years later, by which point Rite Aid was gone. Considerable enforcement attention went to the structure of a transaction while the mechanism actually destroying the industry ran largely unexamined.
By the Numbers
- $17.2 billion at a 48 percent premium — the October 2015 agreement, at $9.00 a share.
- $4.375 billion for 1,932 stores — what actually completed in 2018, roughly a quarter of the original transaction.
- $325 million — the termination fee paid when the merger was abandoned in June 2017.
- 1,200 closures announced in October 2024 — alongside Walgreens’ own description of the model as unsustainable.
- Two bankruptcies and a liquidation — Rite Aid in 2023 and May 2025, ending in full wind-down after 63 years.
- $11.45 a share, August 2025 — the Sycamore take-private, about $10 billion of equity and $23.7 billion including debt.
The Monday Morning Playbook
Four things a sitting operator can do this week:
- Run your segmentation upward before you run it downward. Before analysing which sub-markets you can win, ask whether the category is a winnable cell at all. The finer cut is easier and more satisfying, which is precisely why it gets done first and instead.
- State the doctrinal condition before choosing the play. Consolidation is a healthy-company move. If the honest diagnosis is stagnation, buying more of the same footprint applies the wrong discipline with full rigour.
- Check whether your synergies and your remedies run in opposite directions. Where the most valuable assets are the ones a regulator will require you to divest, the deal cannot be fixed by structuring, only by abandoning it earlier and more cheaply.
- Ask what would have to be true in five years, in writing. Walgreens eventually said the model was unsustainable. The useful exercise is forcing that sentence to be written or refuted at the time of the decision, when it is still an argument rather than a disclosure.
About the Stagnation Assassin
Todd Hagopian is VP of Product Strategy and Marketing at JBT Marel and the author of the Stagnation Assassin series.